BioPharma Resources

Drug Trial Radar · NCT06900010

A Study to Evaluate CM336 in Adults With Autoimmune Bullous Disease

An Open-label, PhaseⅡ Study to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults With Moderate to Severe Autoimmune Bullous Disease

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Apr 22, 2025

Primary completion

Jan 1, 2027

Study completion Jan 1, 2028

Sponsor

Lead sponsor
Shandong First Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults with Moderate to Severe Autoimmune Bullous Disease

Conditions

  • Autoimmune Bullous Disease

Interventions

  • CM336 InjectionBiological

    subcutaneous CM336 administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy after CM336 treatmentTime frame: Up to 52 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Dermatology Hospital of Shandong First Medical University

    Jinan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.